Tryp Therapeutics Current Valuation vs. Beta
| TRYPFDelisted Stock | USD 0.05 0 6.89% |
For Tryp Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Tryp Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Tryp Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Tryp Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Tryp Therapeutics over time as well as its relative position and ranking within its peers.
Tryp |
Tryp Therapeutics Beta vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Tryp Therapeutics's current stock value. Our valuation model uses many indicators to compare Tryp Therapeutics value to that of its competitors to determine the firm's financial worth. Tryp Therapeutics is rated below average in current valuation category among its peers. It is rated below average in beta category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Tryp Therapeutics' earnings, one of the primary drivers of an investment's value.Tryp Current Valuation vs. Competition
Tryp Therapeutics is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Biotechnology industry is at this time estimated at about 1.58 Billion. Tryp Therapeutics adds roughly 4.17 Million in current valuation claiming only tiny portion of stocks in Biotechnology industry.
Tryp Beta vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Tryp Therapeutics |
| = | 4.17 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Tryp Therapeutics |
| = | -1.29 |
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
Tryp Beta Comparison
Tryp Therapeutics is currently under evaluation in beta category among its peers.
Beta Analysis
As returns on the market increase, returns on owning Tryp Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Tryp Therapeutics is expected to outperform it.
Tryp Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Tryp Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Tryp Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Tryp Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Tryp Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Tryp Therapeutics Inc., a pharmaceutical company, focuses on identifying and developing compounds for diseases with high unmet medical needs. The company was incorporated in 2019 and is based in Kelowna, Canada. Tryp Thrapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Tryp Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Tryp Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Tryp Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Tryp Therapeutics' important profitability drivers and their relationship over time.
Use Tryp Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tryp Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tryp Therapeutics will appreciate offsetting losses from the drop in the long position's value.Tryp Therapeutics Pair Trading
Tryp Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Tryp Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tryp Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tryp Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tryp Therapeutics to buy it.
The correlation of Tryp Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tryp Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tryp Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Tryp Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Tryp Therapeutics position
In addition to having Tryp Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Tips ETFs Thematic Idea Now
Tips ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Tips ETFs theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Tips ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in Tryp OTC Stock
If you are still planning to invest in Tryp Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Tryp Therapeutics' history and understand the potential risks before investing.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |